BD, Check-Points Ink Agreement to Develop PCR Kit for Carbapenem-Resistant Organisms | GenomeWeb

NEW YORK (GenomeWeb) – BD today announced a development and global distribution agreement with Netherlands-based Check-Points that will integrate a Check-Points screen with a BD assay within a real time PCR kit that detects carbapenem-resistant organisms (CRO), a healthcare-associated infection, from rectal swabs.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.